Compare BRCB & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BRCB | ARMP |
|---|---|---|
| Founded | 2008 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 179.2M | 199.7M |
| IPO Year | 2025 | 1996 |
| Metric | BRCB | ARMP |
|---|---|---|
| Price | $10.59 | $3.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 2 |
| Target Price | $11.71 | ★ $17.50 |
| AVG Volume (30 Days) | ★ 523.4K | 82.5K |
| Earning Date | 11-10-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $200,321,000.00 | N/A |
| Revenue This Year | $27.52 | N/A |
| Revenue Next Year | $24.44 | N/A |
| P/E Ratio | $138.63 | ★ N/A |
| Revenue Growth | ★ 24.49 | N/A |
| 52 Week Low | $6.11 | $2.75 |
| 52 Week High | $25.20 | $14.98 |
| Indicator | BRCB | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 61.68 | 52.56 |
| Support Level | $6.68 | $3.38 |
| Resistance Level | $15.72 | $3.96 |
| Average True Range (ATR) | 0.83 | 0.37 |
| MACD | 0.05 | 0.09 |
| Stochastic Oscillator | 63.92 | 75.00 |
Black Rock Coffee Bar Inc is an operator of guest-centric, drive-thru coffee bars offering premium caffeinated beverages and an elevated in-store experience crafted by its engaging baristas. The company offers wide variety of coffee from classic espresso-based drinks such as Lattes, Americanos, and Cappuccinos, as well as signature creations like the Caramel Blondie, Mexican Mocha, and Blackout. It offers a variety of savory and sweet items, including breakfast burritos, sausage cheddar sandwiches, banana bread, and glazed donut holes.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.